focus -WSS

focus

author：fashion 2025-10-02 00:35:39 - browse：57

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Bill would stop addiction treatment from triggering child abuse inquiry

Wikipedia

WSS

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

In search for therapies for solid tumors, companies turn to claudin

A virus, fished out of a lake, may have saved a man’s life

What to expect at HLTH 2023, the health care industry conference

Bill would stop addiction treatment from triggering child abuse inquiry

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

International team creates first chimeric human

In age of alternative facts, a scholarly course on calling out crap

Sana to lay off nearly a third of staff, de

As demand for Covid shots wanes, Moderna seeks its next success

How to address the problem of discarded donor organs

Wildfire smoke exposes gaps in outdoor worker protections

Bristol 'take

Malaria cases in Florida and Texas: Here’s what you need to know

FDA does about

entertainment

Chan Zuckerberg Biohub Chicago to focus on inflammation

Clinical trials giant ICON acquires HumanFirst

Senate panel eyes new effort on drug shortages

FDA panel signals lack of confidence in Amgen cancer drug data

Sana to lay off nearly a third of staff, de

A Q&A with the global head of Boehringer Ingelheim's innovation unit

hotspot

explore

hotspot

explore